Last checked at 3 Jul 2017 16:50
E-THERAPEUTICS PLC
("e-Therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND ISSUE OF EQUITY
Oxford, UK, 3 July 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that on 3 July 2017 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 45,364 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") at a price of 12.125 pence per share. The subscription monies paid for the New Ordinary Shares represent 50% of Professor Jones' Non-Executive Director fees net of tax paid during the period from 1 January 2017 to 30 June 2017.
Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on 10 July 2017. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.
Following Admission, Professor Jones will be interested in a total of 212,261 ordinary shares of 0.1p in the Company, representing approximately 0.08% of the Company's issued share capital.
Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 268,471,406. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
The Company previously announced that on 5 October 2016 Professor Jones entered into a binding contractual arrangement with the Company under which he agreed, with effect from 1 October 2016, to invest 50% of his annual Non-Executive Director fees net of tax in new e-Therapeutics' ordinary shares.
The new shares will be issued to Professor Jones on the first business day after 31 December and 30 June in each year. The subscription price to be paid will be the average of the closing mid-market price for the five business days prior to the date of issue. The terms pursuant to which Professor Jones will purchase the shares are fixed, and he has irrevocably committed to such terms.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Trevor Jones |
2 | Reason for the notification | |
a) | Position/status | Non-Executive Director |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | e-Therapeutics plc |
b) | LEI | 21380049RHSSJXWKYT18 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence
ISIN: GB00B2823H99 |
b) | Nature of the transaction | Purchase of shares |
c) | Price(s) and volume(s) | 45,364 ordinary shares at a price of 12.125 pence per share |
d) | Aggregated information - Aggregated volume - Price
| N/A |
e) | Date of the transaction | 3 July 2017
|
f) | Place of the transaction | London Stock Exchange, AIM (XLON) |
For further information, please contact:
Contacts:
E-Therapeutics plc Iain Ross, Chairman Steve Medlicott, CFO
| Tel: +44 (0) 1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Michael Meade/Freddie Barnfield(Corporate Finance) James Black (Corporate Broking)
| Tel: +44 (0) 207 260 1000 www.numis.com
|
Instinctif Partners Melanie Toyne Sewell/Alex Shaw | Tel: +44 (0) 207 457 2020 Email: e-therapeutics@instinctif.com |
About e-Therapeutics plc
e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform. The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.
The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology. The business model is to partner these preclinical drug candidates.
e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.